Li 2006.

Methods	Allocation: randomised. Blindness: single. Duration: 72 hours.
Participants	Diagnosis: CCMD‐3 diagnosis of schizophrenia with agitation/aggression. N = 231. Age: mean 34 (SD 12) years. Sex: males and females. History: mean length of illness, haloperidol group 30 (± 68) months, ziprasidone 18 (± 35) months. Excluded: severe physical or neurological impairment/diseases; drug or alcohol abuse, dependence, pregnant women. Setting: not reported.
Interventions	1. Haloperidol: flexible dose 5 mg/IM to 10 mg/IM, repeated every 4‐6 hours if necessary, maximum dose 30 mg during 24 hours. N = 116. 2. Ziprasidone: flexible dose 10 mg/IM to 20 mg/IM, repeated every 4‐6 hours if necessary, maximum dose 40 mg during 24 hours. N = 115.
Outcomes	Mental state: PANSS endpoint. Agitation: PANSS‐EC. Adverse effects: TESS.
Notes
Risk of bias
Bias	Authors' judgement	Support for judgement
Random sequence generation (selection bias)	Unclear risk	Described as randomised ‐ method of randomisation is not reported.
Allocation concealment (selection bias)	Unclear risk	Not stated.
Blinding of participants and personnel (performance bias) All outcomes	Unclear risk	Single‐blind – however the author did not state who had been blinded.
Blinding of outcome assessment (detection bias) All outcomes	Unclear risk	Single‐blind – however the author did not state who had been blinded.
Incomplete outcome data (attrition bias) All outcomes	Low risk	No incomplete data.
Selective reporting (reporting bias)	Unclear risk	TESS and SAS were used for assessment of adverse events.  No continuous data were reported from either scales, but binary outcomes for adverse events were reported.
Other bias	Unclear risk	None obvious.